BPC-157 dispensed by a 503A pharmacy under a patient-specific prescription is legal in every U.S
A 2-week course of BPC-157 may reduce inflammation and provide some pain relief, but it is unlikely to produce meaningful structural repair
Joint aspiration Removal of excess joint fluid can temporarily bring some relief from pain, but the meniscus will not heal and the fluid will usually reaccumulate
Furthermore, the absence of standardized formulations complicates dose uniformity and treatment reproducibility, as differences in concentration, excipients, or stability across preparations can materially influence therapeutic efficacy and safety outcomes
Sale restricted to registered research entities and laboratories
Get started Well-being and workplace resources Through our well-being and workplace initiatives, APhA offers tools to help pharmacy personnel thrive in healthier and more sustainable ways